Silver Book Fact

Galantamine, a cholinesterase inhibitor, delays Alzheimer’s patients’ need for full-time care, with overall cost savings estimated between $323 and $4,256 per patient.

Caro J, Getsios D, Migliaccio-Walle K, Ishak J, et al. Rational Choice of Cholinesterase Inhibitor for the Treatment of Alzheimer s Disease in Canada: A comparative economic analysis. BMC Geriatrics. 2003; 3(6). http://www.biomedcentral.com/1471-2318/3/6

Reference

Title
Rational Choice of Cholinesterase Inhibitor for the Treatment of Alzheimer s Disease in Canada: A comparative economic analysis
Publication
BMC Geriatrics
Publication Date
2003
Authors
Caro J, Getsios D, Migliaccio-Walle K, Ishak J, et al.
Volume & Issue
Volume 3, Issue 6
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • The U.S. Food and Drug Administration has approved 5 drugs that have proven to temporarily slow the worsening of Alzheimer’s disease symptoms for an average of 6 – 12 months…  
  • Researchers have found how to manipulate embryonic stem cells to form dopamine-producing brain cells. This new source of cells could someday be used to replace cells lost to Parkinson’s.  
  • Impact of Slowed Progression by Stage of Disease, Americans Age 65 and Older with Alzheimer’s Disease, 2050  
  • Medicaid Costs, Slowed Progression  
  • 32 drugs are currently in development for Parkinson’s disease.